We are honored and proud today to announce MannKind is a recipient of the prestigious 2025 Top Workplaces USA award, featured in USA Today. This achievement underscores the organization’s dedication to fostering a people-first workplace culture and prioritizing the employee experience. We celebrate all our Mannitarians who show up with a passion to make life more humann for people living with endocrine and orphan lung diseases. #Proud2BeMNKD #MannKind
MannKind Corporation
制药业
Danbury，CT 14,076 位关注者
Our mission is to give people control of their health and the freedom to live life.
关于我们
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit mannkindcorp.com to learn more.
- 网站
-
https://www.mannkindcorp.com
MannKind Corporation的外部链接
- 所属行业
- 制药业
- 规模
- 201-500 人
- 总部
- Danbury，CT
- 类型
- 上市公司
- 创立
- 1991
地点
MannKind Corporation员工
动态
-
Amsterdam ahead! MannKind is looking forward to participating in the 18th International Conference on Advanced Technologies and Treatments for Diabetes, March 19-22 in Amsterdam. We hope to see you there as conversation focuses on inhaled insulin across five presentations spanning what’s new, first meal results from the INHALE-1 Pediatric trial, and inhaled insulin vs. usual care in adults living with type 1 diabetes. Visit with MannKind and its Clinical Education Team in the exhibit hall (Hall I – Booth 40) to learn more about inhaled insulin and our latest developments in the management of diabetes. #MannKind #ATTD2025 #T1D #Diabetes #DiabetesTechnology
-
-
MannKind has announced that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit and will serve on the company’s executive leadership team. Marasco brings an accomplished track record of more than 25 years of driving commercial success in the biopharma and biotech sectors to his role. More here: https://bit.ly/3PlM1no #MannKind #MNKD?
-
We hope that everyone’s New Year is filled with happiness! Here at MannKind we are excited for a year of innovative ideas that drive us to fulfill our mission of helping give people control of their health.?? #MannKind #NewYearsDay #2025
-
-
MannKind wishes everyone a magical holiday season bountiful with joy and cheer! May the time spent with friends and family be overflowing with lasting memories. #MannKind #HappyHolidays #SeasonGreetings
-
-
MannKind announced its six-month results from the Phase 3 INHALE-1 diabetes trial utilizing inhaled insulin (Afrezza?) study in children and adolescents (aged 4-17 years of age). The company expects to submit a request for a supplemental new drug application (sNDA) meeting with the U.S. Food and Drug Administration (FDA) in 1H 2025 to discuss the data and filing timeline. https://bit.ly/48xsNUu ? #MannKind #Diabetes #T1D #T2D
-
-
With the ICoN-1 study for the treatment of Nontuberculous Mycobacterial (NTM) lung diseases underway in five countries, MannKind makes its way to the 1st North American Bronchiectasis & NTM Symposium held at the NYU Grossman School of Medicine. Eventgoers are invited to come visit with us at Booth 401 or join us over lunch for a presentation on MannKind’s Phase 3 study (ICoN-1) of Inhaled Clofazimine in adults with NTM. Dr. Wassim Fares will present at this industry event and host a discussion following alongside colleague Chris Rose. #MannKind #Pulmonary #NTM
-
-
UDPATED - Additional Panelist. Don't miss this #HBALA event with interactive breakouts and a moderated panel on the topic of: "Charting Your Future: Strategies for Success", sponsored and hosted by MannKind Corporation. Learn strategies to transform your career and build your personal brand. ?? Distinguished panelists: Cynthia Deignan, Executive Director, Global Medical Affairs, Amgen Johanna Ulloa, Executive Director, Clinical Operations, MannKind Corporation Nancy Wongvipat Kalev, MPH, Senior Director, Systems of Care, Health Net Moderator: Stuart Tross, Chief People and Workplace Officer, MannKind Corporation ?? Wednesday, December 11 from 5-8 pm PST ??MannKind Corporation, 30930 Russell Ranch Road, Suite 300, Westlake Village ?? Unique Interactive Format: - Networking - Facilitated Breakout Discussions - Moderated Panel Register at: https://lnkd.in/giQ7Y2Ms #HBALA #HBAimpact #networking #biotech Poornima Shubhakar Helen McBride Shannon Lee Topinka, MBA, PMP Elizabeth Watt, PhD Kamala Lakamsani Marielle Hajducko Segolene Reille Tracy Nanfito Jamie Wells Ana Romero, MBA, PMP, LSSBB, CSM Jennifer Turcotte Nancy Watanabe Lorena Griparic, Ph.D.
-
-
Let's keep the conversation going... #DiabetesAwarenessMonth
I am truly honored to have chaired the recent American Diabetes Association? 2024 State of Diabetes event on World Diabetes Day, November 14. It was a privilege to moderate a panel of esteemed experts across various sectors to discuss the current landscape of diabetes. The event - Dollars & Diabetes: Counting the Costs – highlighted the pressing realities of diabetes care in the U.S., now recognized as the most expensive chronic disease. Together, we explored tangible outcomes to enhance diabetes care, promote workplace wellness, and strengthen advocacy efforts. The insights shared were invaluable, and I am inspired by the collective commitment to improving the lives of those affected by diabetes. This opportunity was particularly special for me as the event took place at USC, where I had the chance to tour the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, named in honor of our founder, Al Mann. It was a poignant reminder of the legacy we continue to build upon at MannKind. Let’s keep the conversation going and work together towards a healthier future for all! ?? #MannKind #Advocacy #AmericanDiabetesMonth #WDD #T1D #T2D #USCMann
-
-
MannKind looks to meet with the FDA in 1H 2025 on the heels of successfully completing its Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including IPF. Nintedanib DPI was shown to be safe and well tolerated in healthy volunteers, meeting its primary objective. Participants did not experience typical adverse events – specifically, no GI or neurological AEs – seen with oral nintedanib. More details: https://bit.ly/48xsNUu #MNKD #Pulmonary #PulmonaryFibrosis #IPF
-